Literature DB >> 15132789

[Association between a genomic polymorphism within the CD14 locus and severe sepsis susceptibility as well as prognosis in patients after extensive burns].

Jing Lin1, Yong-ming Yao, Zhi-hong Huang, Xiao-xia Hou, Jing-min Zhu, Jia-ke Chai.   

Abstract

OBJECTIVE: To investigate the relation of a lipopolysaccharide receptor CD14C-159T gene polymorphism to severe sepsis susceptibility and prognosis in patients with extensive burns.
METHODS: The study group consisted of 118 normal controls and 16 patients with burns covering more than 60 percent total body surface area. Typing of each patient for the CD14C-159T gene polymorphism was performed by analyzing restriction fragments of a Hae III-digested DNA fragment obtained using polymerase chain reaction (PCR-RFLP). Genotypes were then related to the susceptibility and mortality rate of severe sepsis.
RESULTS: The overall allele frequency (C 43.7 percent, T 56.3 percent) and genotype distribution (C homozygous 12.5 percent, C/T 62.5 percent, T homozygous 25.0 percent) were in agreement with the distribution in healthy volunteers. Genotype distribution in patients with severe sepsis was different from that in patients with an uncomplicated clinical course. Development of severe sepsis was increased in patients homozygous for the allele T (71.4 percent) than that of the non- sepsis patients (44.4 percent).
CONCLUSION: The single base pair polymorphism at position-159 in the CD14 gene promoter might influence the development of severe sepsis in patients with extensive burns.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15132789

Source DB:  PubMed          Journal:  Zhongguo Wei Zhong Bing Ji Jiu Yi Xue        ISSN: 1003-0603


  1 in total

1.  Association between the -159C/T polymorphism in the promoter region of the CD14 gene and sepsis: a meta-analysis.

Authors:  Qin Wu; Xiaomeng Xu; Jianan Ren; Song Liu; Xuelian Liao; Xiuwen Wu; Dong Hu; Gefei Wang; Guosheng Gu; Yan Kang; Jieshou Li
Journal:  BMC Anesthesiol       Date:  2017-01-25       Impact factor: 2.217

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.